Podophyllotoxin and its derivatives were examined for inhibitory effects on the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), including acyclovir-resistant virus and clinical isolates. Deoxypodophyllotoxin (RD4–6266) proved to be a highly potent and selective inhibitor of all HSV strains in MRC-5 cells. EC50 values of RD4–6283 (in which the methylenedioxy ring A is modified) for HSV-1 and -2 were inferior to those of deoxypodophyllotoxin. However, podorhizol (RD4–6277) and 5′-methoxy-podorhizol (RD4–6276), in which ring C is absent, did notinhibit HSV replication. Moreover, RD4–6266 also inhibited the production of infectious virus particles of HSV-1 KOS strain and HSV-2 G strain. In contrast, none of the podophyllotoxin derivatives were found to have an antiviral effect against influenza A virus, respiratory syncytial virus or human cytomegalovirus in doses not toxic to the cells.
BeersSAImakuraYDaiHJLiDHChengYC & LeeKH (1988) Antitumor agents, 99. Synthetic ring C aromatized podophyllotoxin analogues as potential inhibitors of human and topoisomerase II. Journal of Natural Production51:901–905.
2.
BeutnerKR & von KroghG (1990) Current status of podophyllotoxin for the treatment of genital warts. Seminars in Dermatology9:148–151.
3.
BonnezMElswickRKJrBailey-FarchioneAHallahanDBellRIsenbergRStolerMH & ReichmanRC (1994) Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. American Journal of Medicine96:420–425.
4.
ChatisPA & CrumpackerCS (1992) Resistance of herpesviruses to antiviral drugs. Antimicrobial Agents & Chemotherapy36:1589–1595.
5.
ChenGLYangLRoweTCHalliganBDTeweyKM & LiuLF (1984) Nonintercalative antitumor drugs interfere with the breakage–reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry259:13560–13566.
6.
CoenDM (1991) The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Research15:287–300.
7.
CrumpackerCSSchnipperLEMarloweSIKowalskyPNHersheyBJ & LevinMJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. New England Journal of Medicine306:343–346.
8.
EbertSNShtromSS & MullerMT (1990) Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent. Journal of Virology64:4059–4066.
9.
EbertSNSubramanianDShtromSSChungIKParrisDS & MullerMT (1994) Association between the p170 form of human topoisomerase II and progeny viral DNA in cells infected with herpes simplex virus type 1. Journal of Virology68:1010–1020.
10.
GordalizaMCastroMAGarcia GravalosMDRuizPMiguel del CorralJM & San FelicianoA (1994) Antineoplastic and antiviral activities of podophyllotoxin related lignans. Archives of Pharmacology327:175–179.
11.
HammarstenOYaoX & EliasP (1996) Inhibition of topoisomerase II by ICRF-193 prevents efficient replication of herpes simplex virus type 1. Journal of Virology70:4523–4529.
12.
HansenHFJensenRBWillumsenAMNorskov-LauritsenNEbbesenPNielsenPE & BuchardtO (1993) New compounds related to podophyllotoxin and congeners: synthesis, structure elucidation and biological testing. Acta Chemica Scandanavica47:1190–1200.
13.
LoikeJD & HorowitzSB (1976) Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry15:5435–5442.
14.
LoikeJDBrewerCFSternlichtHGenslerWJ & HorwitzSB (1978) Structure–activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Research38:2688–2693.
15.
Manso-MartinezR (1982) Podophyllotoxin poisoning of micro-tubules at steady-state: effect of substoichometic and superstoichometic concentration of drug. Molecular and Cellular Biochemistry45:3–11.
16.
MascheraBFerrazziERassuMToniM & PaluG (1993) Evaluation of topoisomerase inhibitors as potential antiviral agents. Antiviral Chemistry & Chemotherapy4:85–91.
17.
McLarenCChenMSGhazzouliISaralR & BurnsWH (1985) Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrobial Agents & Chemotherapy28:740–744.
18.
NishiyamaYFujiokaHTsurumiTYamamotoNMaenoKYoshidaS & ShimokataK (1987) Effects of the epipodophyllotoxin VP-16-213 on herpes simplex virus type 2 replication. Journal of General Virology68:913–918.
19.
San FelicianoAMedardeMPelaez Lamamie de ClairacRLopezJLPueblaPGarcia GravalosMDRuiz LazaroP & Garcia de QuesadaMT (1993) Synthesis and biological activity of bromolignans and cyclolignans. Archives of Pharmacology326:421–426.
20.
SavelH (1964) Clinical experiment with intravenous podophyllotoxin. Proceedings of the American Association for Cancer Research5:56.
21.
StoneKM (1995) Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clinical Infectious Diseases20(Suppl. 1):S91–97.
22.
StraussMJKhannaVKoenigJDDownsSMGlodbergSHManyakMJ & PatsnerB (1996) The cost of treating genital warts. International Journal of Dermatology35:340–348.
23.
SudoKKonnoKYokotaT & ShigetaS (1994) A sensitive assay system screening antiviral compounds against herpes simplex virus type 1 and type 2. Journal of Virological Methods49:169–178.
24.
TeradaTFujimotoKNomuraMYamashitaJKobunaiTTakedaSWierabaKYamadaY & YamaguchiH (1992) Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Chemical and Pharmaceutical Bulletin40:2720–2727.
25.
von KroghG & MaibachHI (1983) Cutaneous cytodestructive potency of lignans. II. A comparative evaluation of macroscopic-toxic influence on rabbit skin subsequent to repeated 10–day applications. Dermatologica167:70–77.
26.
WhitleyRJ (1988) Herpes simplex virus infection of central nervous system: a review. American Journal of Medicine85(Suppl. 2A):61–67.
